Literature DB >> 16196234

Treatment of refractory sarcoidal parotid gland swelling in a previously reported unresponsive case.

Louis Mandel1, Barry Wolinsky, Elizabeth C Chalom.   

Abstract

BACKGROUND: Sarcoidosis is a multisystem granulomatous disease that is seen occasionally in patients with characteristic bilateral parotid gland swelling. Conventional therapy has involved either no treatment because of spontaneous remission or corticosteroids when organ involvement is severe. CASE DESCRIPTION: The authors describe a previously published case report of a patient with sarcoidosis with parotid gland swellings who did not respond to standard therapy. Despite the use of various immunosuppressive agents, the swellings failed to resolve over a three-year period. It was only after a newly recommended agent, infliximab, was used that the patient's condition was treated successfully. CLINICAL IMPLICATIONS: It is important for dental practitioners to be familiar with manifestations of sarcoidosis, particularly its salivary gland aspects. Inherent in the knowledge of the disease is the therapeutic approach to both routine and recalcitrant

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16196234     DOI: 10.14219/jada.archive.2005.0345

Source DB:  PubMed          Journal:  J Am Dent Assoc        ISSN: 0002-8177            Impact factor:   3.634


  4 in total

Review 1.  Sarcoidosis and its otolaryngological implications.

Authors:  Katarzyna Mrówka-Kata; Dariusz Kata; Dariusz Lange; Grzegorz Namysłowski; Eugeniusz Czecior; Katarzyna Banert
Journal:  Eur Arch Otorhinolaryngol       Date:  2010-07-09       Impact factor: 2.503

2.  [Sarcoidosis of lymph nodes in the submandibular compartment].

Authors:  T Braun; V Siedek; G Assmann; S Ihrler; S Kirchhoff; V Vielhauer; R de la Chaux
Journal:  HNO       Date:  2010-04       Impact factor: 1.284

3.  Infliximab therapy for hepatic and intestinal sarcoidosis.

Authors:  Helen S Te; Lucas Campbell; Saima Chohan
Journal:  Gastroenterol Hepatol (N Y)       Date:  2007-06

4.  Tumor necrosis factor-alpha inhibitor treatment for sarcoidosis.

Authors:  José Luis Callejas-Rubio; Lourdes López-Pérez; Norberto Ortego-Centeno
Journal:  Ther Clin Risk Manag       Date:  2008-12       Impact factor: 2.423

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.